Filing Flows

Filing Flows › Companies › Medicinova › Cash flow

Medicinova cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$1.9M in Q2 2026 · −$9.1M over twelve months

Operating cash flow−$1.9M
Free cash flow−$1.9M

Analysis

In Q2 2026, Medicinova generated −$1.9M of operating cash flow. That is $386K more than in Q2 2025 (−$2.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$9.1M; the largest uses were operating cash flow ($9.1M), capital spending ($14K); the cash balance fell by $8.8M.

Operating cash flow was −$1.9M against net income of −$2.3M. The largest differences: deferred revenue −$428K, receivables +$245K, stock-based pay +$177K.

Free cash flow

Medicinova: free cash flow by quarterMedicinova: free cash flow by quarter−$2.0MQ3 2024−$1.9MQ4 2024−$3.8MQ1 2025−$2.3MQ2 2025−$1.7MQ3 2025−$2.0MQ4 2025−$3.5MQ1 2026−$1.9MQ2 2026
Operating cash flow less capital spending.
Medicinova: operating cash flow against capital spendingMedicinova: operating cash flow against capital spendingOperating cash flowCapital spending−$2.0M$6Q3 2024−$1.9M−$2Q4 2024−$3.8M$0Q1 2025−$2.3M$0Q2 2025−$1.7M$3KQ3 2025−$2.0M$0Q4 2025−$3.5M$11KQ1 2026−$1.9M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$1.9M, Capital spending $0.

Capital allocation, year by year

Medicinova: where the cash came from (up) and went (down), by fiscal yearMedicinova: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$9.4MFY2021: Shares issued $6KFY2021: Capital spending −$29K$6KFY2021FY2022: Operating cash flow −$12.9MFY2022: Capital spending −$5KFY2022FY2023: Operating cash flow −$7.4MFY2023: Capital spending −$21KFY2023FY2024: Operating cash flow −$10.6MFY2024: Asset sales $198FY2024: Capital spending −$1K$198FY2024FY2025: Operating cash flow −$9.8MFY2025: Shares issued $244KFY2025: Capital spending −$3K$244KFY2025
Over these 5 years operating cash flow totalled −$50.2M; the largest uses were operating cash flow ($50.2M) and capital spending ($59K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$25.4M
Debtnone
Net cash$25.4M
Cash runway2.8 years

Medicinova is burning cash: its operations consume cash, a free cash flow of −$9.1M a year at the current rate against $25.4M of cash and investments: a runway of about 2.8 years before any new financing.

Where the cash came from and went

Medicinova: sources (+) and uses (−) of cash, Q2 2026Medicinova: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$1.9MCash drawn (+) / kept (−)$1.9MExchange rates$7K
Medicinova: sources (+) and uses (−) of cash, TTM to Q2 2026Medicinova: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$9.1MCash drawn (+) / kept (−)$8.8MNot reconciled$244KExchange rates$36KCapital spending−$14K

From profit to cash

Medicinova: net income to operating cash flow, Q2 2026Medicinova: net income to operating cash flow, Q2 2026Net income−$2.3MDepreciation & amortization$5KStock-based pay$177KReceivables$245KDeferred revenue−$428KPrepaid and other assets$66KOperating cash flow−$1.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingCash drawn (+) / kept (−)Free cash flow
Q2 2026−$1.9M—$1.9M−$1.9M
Q1 2026−$3.5M−$11K$3.5M−$3.5M
Q4 2025−$2.0M—$1.8M−$2.0M
Q3 2025−$1.7M−$3K$1.7M−$1.7M
Q2 2025−$2.3M—$2.3M−$2.3M
Q1 2025−$3.8M—$3.8M−$3.8M
Q4 2024−$1.9M$2$1.9M−$1.9M
Q3 2024−$2.0M−$6$2.1M−$2.0M

Medicinova: income statement and cash flow

Medicinova, Q2 2026: revenue $458K (+241% year over year), operating margin -554.3%. The chart follows the revenue to costs, profit and cash.

Medicinova: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.